A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma

REFERENCES

• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   Google Scholar
• Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562 — 3568.
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemother-apy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   Google Scholar
• Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327: 1342–1349.
   Google Scholar
• Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and valida-tion of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Chin Oncol 1991;9:211 — 219.
   Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   Google Scholar
• Canellos GP, Anderson Jr, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327: 1478–1484.
   Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Chin Oncol 1994;12: 1169–1176.
   Google Scholar
• Haw R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Chin Oncol 1994;12:1074–1084.
   Google Scholar
• Bosly A, Coiffier B, Gisselbrecht C, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Chin Oncol 199210:1615-1623.
   Google Scholar
• Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990;76:1293–1298.
   Google Scholar
• Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693–697.
   Google Scholar
• Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Chin Oncol 1987;5:407–412.
   Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117–122.
   Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemother-apy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   Google Scholar
• Armitage JO. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989;73:1749–1758.
   Google Scholar
• Bearman SI, Appelbaum FR, Back A, et al. Regimen-related toxicity and early post-transplant survival in patients under-going marrow transplantation for lymphoma. J Chin Oncol 1989;7:1288–1294.
   Google Scholar
• Colombat P, Gorin NC, Lemonnier MP, et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas. J Chin Oncol 1990;8:630–637.
   Google Scholar
• Moskowitz CH, Bertino Jr, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lympho-ma. J Chin Oncol 1999;17:3776–3785.
   Google Scholar
• Aurlien E, Holte H, Pharo A, et al. Combination chemother-apy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998;21:873–878.
   Google Scholar
• Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lym-phoma 1995;18:123–129.
   Google Scholar
• Cerny T, Castiglione M, Brunner K, Kupfer A, Martinelli G, Lind M. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990;335:175.
   Google Scholar
• Coleman M, Leonard J, Shuster MW, Kaufman TP. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol Suppl 2001;64:41–45.
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
   Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Chin Trials 1996;17:343–346.
   Google Scholar
• MathSoft I. S-PLUS 2000. Seattle, WA; 1999.
   Google Scholar
• CYTEL. StatXact (ed 5.0.3). Cambridge, MA; 2001.
   Google Scholar
• King K, Younes A. Ifosfamide- and paclitaxel-based treat-ment of relapsed and refractory lymphoma. Semin Oncol 2000;27:14–22.
   Google Scholar
• Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol 2003;14 Suppl 1:ill - 16.
   Google Scholar
• Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003;14 Suppl 1:i17–i20.
   Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   Google Scholar
• Xiros N, Economopoulos T, Valsami S, Rontogianni D, Fountzilas G, Raptis S. Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with pri-mary refractory or early relapsed T cell rich B cell lymphoma. A pilot study. Leuk Res 2003;27:1097–1099.
   Google Scholar
• Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004;15:511–516.
   Google Scholar
• Gisselbrecht C, Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Semin Oncol 2004;31:12–16.
   Google Scholar
• Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990;39:438–490.
   Google Scholar
• Reiser M, Schnell R, Straub G, et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998; 31:359–366.
   Google Scholar